Evidence map›Paper›PMID 35008657›Full record

ArticleInternational journal of molecular sciences2021

Novel 1,3,5-Triazinyl Aminobenzenesulfonamides Incorporating Aminoalcohol, Aminochalcone and Aminostilbene Structural Motifs as Potent Anti-VRE Agents, and Carbonic Anhydrases I, II, VII, IX, and XII Inhibitors.

Eva Havránková, Vladimír Garaj, Šárka Mascaretti, Andrea Angeli, Zuzana Soldánová, Miroslav Kemka, Jozef Motyčka, Marie Brázdová, Jozef Csöllei, Josef Jampílek and 1 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Progress of Section "Biochemistry" in 2022.International journal of molecular sciences · 2023
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Eva HavránkováDepartment of Chemical Drugs, Faculty of Pharmacy, Masaryk University, Palackého 1-3, 612 42 Brno, Czech Republic.
Vladimír GarajDepartment of Pharmaceutical chemistry, Faculty of Pharmacy, Comenius University, Odbojarov 10, 832 32 Bratislava, Slovakia.ORCID 0000-0002-8229-414X
Šárka MascarettiCzech Advanced Technology and Research Institute, Palacky University, Slechtitelu 27, 783 71 Olomouc, Czech Republic.
Andrea AngeliSection of Farmaceutical and Neutraceutical Sciences, Neurofarba Department, University of Florence, 50019 Sesto Fiorentino, Italy.ORCID 0000-0002-1470-7192
Zuzana SoldánováDepartment of Molecular Pharmacy, Faculty of Pharmacy, Masaryk University, Palackého 1-3, 612 42 Brno, Czech Republic.
Miroslav KemkaDepartment of Pharmaceutical chemistry, Faculty of Pharmacy, Comenius University, Odbojarov 10, 832 32 Bratislava, Slovakia.
Jozef MotyčkaDepartment of Pharmaceutical Analysis and Nuclear Pharmacy, Faculty of Pharmacy, Comenius University, Odbojarov 10, 832 32 Bratislava, Slovakia.
Marie BrázdováDepartment of Molecular Pharmacy, Faculty of Pharmacy, Masaryk University, Palackého 1-3, 612 42 Brno, Czech Republic.
Jozef CsölleiDepartment of Chemical Drugs, Faculty of Pharmacy, Masaryk University, Palackého 1-3, 612 42 Brno, Czech Republic.
Josef JampílekDepartment of Chemical Biology, Faculty of Science, Palacky University, Slechtitelu 27, 783 71 Olomouc, Czech Republic.ORCID 0000-0003-2003-9052
Claudiu T SupuranSection of Farmaceutical and Neutraceutical Sciences, Neurofarba Department, University of Florence, 50019 Sesto Fiorentino, Italy.ORCID 0000-0003-4262-0323
Masaryk University · CZComenius University Bratislava · SKUniversity of Florence · ITRegional Centre of Advanced Technologies and Materials · CZSlovak Academy of Sciences · SK

Funding

INGA MU, with the support of the Specific University Research Grant, as provided by the Ministry of Edu-cation, Youth and Sports of the Czech Republic in the year 2020 MUNI/A/1202/2020Slovak Research and Development Agency APVV-18-0302
6 · The paper itself

Abstract

A series of 1,3,5-triazinyl aminobenzenesulfonamides substituted by aminoalcohol, aminostilbene, and aminochalcone structural motifs was synthesized as potential human carbonic anhydrase (hCA) inhibitors. The compounds were evaluated on their inhibition of tumor-associated hCA IX and hCA XII, hCA VII isoenzyme present in the brain, and physiologically important hCA I and hCA II. While the test compounds had only a negligible effect on physiologically important isoenzymes, many of the studied compounds significantly affected the hCA IX isoenzyme. Several compounds showed activity against hCA XII; (

Indexed as

Anti-Bacterial AgentsAntineoplastic AgentsCarbonic Anhydrase ICarbonic Anhydrase IICarbonic Anhydrase InhibitorsCarbonic Anhydrase IXCarbonic AnhydrasesHCT116 CellsHumansMolecular Docking SimulationMolecular Dynamics SimulationNeoplasmsStructure-Activity RelationshipSulfonamidesVancomycin-Resistant EnterococciAnti-Bacterial AgentsAntineoplastic AgentsCarbonic Anhydrase ICarbonic Anhydrase IICarbonic Anhydrase InhibitorsCarbonic Anhydrase IXCarbonic Anhydrasescarbonic anhydrase XIISulfonamidesbenzenesulfonamidecarbonic anhydrasechalconeinhibitionstilbenetriazinevancomycin-resistant enterococci

Identifiers

PMID35008657
PMCPMC8745223
OpenAlexW4200247137

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.